Published by: BiotechPrimer Written by: Emily Burke, PhD For many years, a diagnosis of acquired immunodeficiency syndrome (AIDS) was a death sentence. It seemed unthinkable in the 1980s, but the medical community now largely treats the disease as a chronic illness. This profound shift arose through the development of highly active antiretroviral therapies (HAART). These medicines… [Read More]
The Gene Fix That Might Cure HIV
Published by: One Zero Written by: Emily Mullin Antiretroviral drugs make HIV manageable, but gene therapies could eliminate the virus altogether — provided the treatments can be made safe and economical In the mid-1990s, scientists made a curious but remarkable discovery: A man named Stephen Crohn seemed virtually immune to HIV. In the years before that discovery,… [Read More]
Montgomery Magazine: “Jeffrey Galvin’s BioTech Firm May Be on The Verge of Curing HIV/AIDS”
Published by: Montgomery Magazine | Issue: August – September 2019, Page 42 Written by: Jeff Thoreson | Photograph by: Kevin Allen A 3D RENDERING OF HIV VIRUS IN BLOOD STREAM Jeffrey Galvin has been a computer nerd since the seventh grade. Way back in the 1970s era of mainframes, he became interested not so much… [Read More]
C&EN: “How Phenylketonuria, A Once-Neglected Disease, Became A Proving Ground For New Drugs”
Published by: C&EN on May 12, 2019, In: Volume 97, Issue 27. Written by: Ryan Cross After decades of yearning for drugs, people with PKU now have 2, and a dozen more are in development. It’s dinnertime on a Wednesday evening in June at the Wards’ house in Whitman, Massachusetts. As Karen Ward calls her… [Read More]
HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV
ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use… [Read More]
C&EN: “With Several Long-acting HIV Treatments In The Works, The Newest Drugs Emphasize Convenience”
Published by: C&EN on May 12, 2019, In Volume 97, Issue 19. Written by: Megha Satyanarayana Lionel Hillard’s boss asked him to come into his office. It was the late 1980s in Dallas. The then 29-year-old was a medical assistant at a busy clinic with a room full of patients. But the doctor who ran… [Read More]
Site Selection: “The Future of Healthcare is Here: Maryland Leads a Biotech Revolution”
Published by: Site Selection, Digital Edition, May 2019 Issue. Written by: Gary Daughters Jeff Galvin, founder and CEO of Rockville, Maryland’s American Gene Technologies, speaks of cellular gene therapy with the zeal of an evangelist. “I believe we’re on the eve of a gene and cell therapy revolution that will completely disrupt the traditional drug… [Read More]
Washington Post: “New CDC Chief Stepped Down From Four Groups to Comply With Ethics Rules”
Published by: The Washington Post. Written by: Lena H. Sun Centers for Disease Control and Prevention Director Robert Redfield has resigned his positions at four groups, including a gene therapy biotechnology company and a conservative AIDS organization, to comply with government ethics rules, according to his financial disclosures. Redfield, a longtime HIV/AIDS researcher who started the job… [Read More]
Wall Street Journal: “New CDC Chief Resigned From Four Entities to Comply With Ethics Rules”
Published by: The Wall Street Journal. Written by: Betsy McKay Updated: April 17, 2018 11:09 am ET Financial disclosures detail steps Robert Redfield has taken; ethics office found him to be in compliance The new director of the Centers for Disease Control and Prevention resigned positions at four entities, sold stock and forfeited options in… [Read More]
HIV Cure Program Patent Granted To American Gene Technologies
ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous cell products to treat HIV… [Read More]
